BLACK DIAMOND THERAPEUTICS, INC. Number of Reportable Segments
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- BLACK DIAMOND THERAPEUTICS, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |